GlobeNewswire

Corvil Says Standards, Collaboration and AI-Powered Automation are Critical to Building Cyber Resilience in Global Financial Markets

Dela

As leaders in the trading community gather for the FIX Trading Community, 2018 EMEA Trading Conference, Corvil shines spotlight on cyber risks in algorithmic trading

 

DUBLIN, Ireland, March 15, 2018 (GLOBE NEWSWIRE) -- Corvil Director, Security Product Management, Graham Ahearne, is among the cybersecurity panelists at today's FIX Trading Community Annual EMEA Conference, enlisted to address how financial markets can mitigate cyber risk.

While most financial institutions have robust information security solutions and programmes in place, outmaneuvering today's advanced cyber attackers, who have industrialised their tactics, techniques and procedures, remains one of the biggest operating challenges. The risk should not be underestimated with regulators such as Steve Peikin, co-director of the U.S. Security and Exchange Commission (SEC), warning last year: "The greatest threat to our markets right now is the cyber threat."

Industry associations such as the FIX Trading Community are playing a key role in spearheading standards to mitigate risks. January 2018 saw the release of the FIX-over-TLS (FIXS) standard and guidelines to help users of the FIX protocol meet security requirements. FIXS is part of a larger programme of work that the FIX Trading Community initiated in response to the cybersecurity challenge.

In supporting FIX's cyber initiatives Graham Ahearne says: " The advanced, persistent threat landscape poses an enormous risk to financial markets.  The significance of industry collaboration and knowledge sharing cannot be overstated, which is why events like FIX EMEA conference are critically important. "

Trading environments tend to be optimized for one thing: speed. Nowhere else in the world is data moving this fast, in such large volumes, with so much economic value at stake. Performance and speed are paramount, and trading networks do not want additional overhead to weigh them down, which makes adding traditional security systems challenging.

Ahearne says: " There is also a perception, because they are typically segmented from the rest of the enterprise IT infrastructure, that trading environments are safer than others.  With more than 80 percent of breaches [1]  stemming from accidental mishaps or malicious insiders, these environments can become compromised ."

While in a normal attack, hackers may need to steal data or install ransomware, in financial markets, hackers only need to slightly tweak an algorithm or impair the performance of the network overall. Electronic trading networks are heavily automated, but they play such a huge role in the stock market at large that a rogue trading algorithm could do significant damage.

Whether dealing with nation state attackers, criminals, hacktivists, or simply careless employees, CISOs in financial markets have now taken on the unique role of an independent risk monitor watchdog. Corvil believes AI-powered automation and advanced analytics will also play a big role in the way forward.

Optimal cyber security needs to understand the content of communications, as well as patterns and types of communication. Different, anomalous and malicious content along the same communication paths, tendencies, and applications may still constitute a breach. The only way to govern the proper function of algorithms is by watching over the machines themselves - not just what they are doing, but what they are actually saying to each other.

FIX Trading Community is the non-profit, industry-driven standards body at the heart of global financial trading. The 2018 EMEA Trading Conference takes place on 15 March 2018 and will cover the most pressing issues facing the institutional trading community and provide a neutral platform for buy-side, sell-side, exchanges, vendors and regulators to share their ideas on how the community can continue to collaborate. Graham joins fellow panelists Ian Glover, President, CREST; Charles Kilkenny, CEO, Actuare and Russell Wing, Head of Information Security, LME on the "Mitigating Cyber Risk" panel session which is moderated by Julia Streets, Founder & CEO, Streets Consulting Ltd.

About Corvil
Corvil is the industry leader for deriving Security, Operational, and Business intelligence from network data. As companies adopt faster and smarter machine technology, it becomes critical to tap into richer and more granular machine data sources to safeguard the transparency, performance and security of critical infrastructure and business applications. The Corvil streaming analytics platform captures, decodes, and learns from network data on the fly, transforming it into machine-time intelligence for network, IT, security and business teams to operate efficiently and securely in this new machine world. Corvil uses an open architecture to integrate the power of its network data analytics with the overall IT ecosystem providing increased automation and greater operational and business value outcomes for its users. The Corvil solution is trusted by leading financial institutions to safeguard their businesses across the globe involving 354 trillion messages with a daily transaction value in excess of $1 trillion.
Learn more about Corvil: Corvil.com | Twitter | LinkedIn 

Notes to editor:

[1] 81% of hacking-related breaches leveraged either stolen and/or weak passwords - 2017 Verizon DBIR.

Media Contact
Press Office at Corvil
+353 1 859 1040
pressoffice@corvil.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corvil via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum